Xortx Therapeutics Inc (XRTX)

$2.62

+0.04

(+1.55%)▲

Live

Performance

  • $2.53
    $2.70
    $2.62
    downward going graph

    3.44%

    Downside

    Day's Volatility :6.3%

    Upside

    2.96%

    downward going graph
  • $1.98
    $67.72
    $2.62
    downward going graph

    24.43%

    Downside

    52 Weeks Volatility :97.08%

    Upside

    96.13%

    downward going graph

Returns

PeriodXortx Therapeutics IncIndex (Russel 2000)
3 Months
-25.0%
0.0%
6 Months
5.31%
0.0%
1 Year
273.21%
0.0%
3 Years
-17.83%
-22.6%

Highlights

Market Capitalization
7.5M
Book Value
$1.02
Earnings Per Share (EPS)
-1.38
Wall Street Target Price
12.2
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-31.0%
Return On Equity TTM
-57.92%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-3.9M
Diluted Eps TTM
-1.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.22
EPS Estimate Next Year
-1.68
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 5 Wall street analysts offering stock ratings for Xortx Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 5 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 365.65%

Current $2.62
Target $12.20

Technicals Summary

Sell

Neutral

Buy

Xortx Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xortx Therapeutics Inc
Xortx Therapeutics Inc
-2.64%
5.31%
273.21%
-17.83%
-17.83%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xortx Therapeutics Inc
Xortx Therapeutics Inc
NA
NA
NA
-2.22
-0.58
-0.31
NA
1.02
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xortx Therapeutics Inc
Xortx Therapeutics Inc
Buy
$7.5M
-17.83%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Bank of Montreal

    0.52%

  • BMO Capital Markets Corp.

    0.52%

  • Advisor Group Holdings, Inc.

    0.04%

  • Hartland & Co

    0.01%

  • JPMorgan Chase & Co

    0.01%

Company Information

xortx therapeutics inc., a bio-pharmaceutical company, focuses on the development and commercialization of therapies to treat progressive kidney diseases worldwide. it has two lead programs, including treatments for progressive kidney disease due to diabetes, diabetic nephropathy and polycystic kidney disease. the company focuses on developing therapies for health consequences that includes pre-diabetes, diabetes, and cardiovascular disease. in addition, it develops uric acid lowering agents to treat diabetic nephropathy, hypertension, insulin resistance, metabolic syndrome, and diabetes; and xanthine oxidase inhibitors. the company has a strategic alliance with teijin pharma limited to develop tmx-049, a xanthine oxidoreductase; and a partnership with the icahn school of medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with covid-19. xortx therapeutics inc. is headquartered in calgary, canada.

Organization
Xortx Therapeutics Inc
Employees
2
CEO
Dr. Allen Warren Davidoff Ph.D.
Industry
Miscellaneous

Discover More

FAQs